Cutaneous Oncology News

Victor Sandor, MD, chief medical officer of Array Biopharma, spoke with HemOnc Today about the FDA’s approval of a two-drug combination for a subset of patients with melanoma.

The FDA approved the combination of encorafenib and binimetinib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or BRAF V600K mutation.

Survivin, an inhibitor of apoptosis protein, may be an attractive target for a variety of immunotherapeutic approaches for cancer, according to study results.

CHICAGO — Danny Rischin, MBBS, FRACP, MD, director of the division of cancer medicine and head of the medical oncology department at Peter MacCallum Cancer Centre in Australia, spoke with HemOnc Today at ASCO Annual Meeting about research into cemiplimab.

The FDA granted expanded clearance to the Paxman Scalp Cooling System, allowing the device to be used by patients with any type of solid tumor.

A form of artificial intelligence known as a deep learning convolutional neural network appeared more effective than experienced dermatologists for melanoma detection, according to results of a comparative cross-sectional study.

Patients classified as high users of hydrochlorothiazide had a higher risk for melanoma, according to findings published in JAMA Internal Medicine.

DESTIN, Fla. — Although the incidence of rheumatologic adverse effects associated with immune checkpoint inhibitors is expected to grow with their increased use, these effects remain poorly studied in random clinical trials, according to findings presented at the 2018 Congress of Clinical Rheumatology.

The FDA approved the combination of dabrafenib and trametinib for adjuvant treatment of patients with BRAF V600E- or BRAF V600K-positive melanoma that has spread to their lymph nodes.

The FDA granted priority review to cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma or those with locally advanced disease who are not candidates for surgery.